Semi-live respiratory syncytial virus vaccine
AssigneeAmvac AG
InventorsMarian WIEGAND, Christine KAUFMANN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a semi-live respiratory syncytial virus (RSV) vaccine, which comprises a genome replication-deficient Sendai virus (SeV) vector expressing a chimeric RSV/SeV F protein. Furthermore, the present invention relates to a method for the production of the genome replication-deficient SeV vector of the present invention, and the use thereof in the treatment of RSV infections and RSV infection-related diseases.
Claims15
A genome replication-deficient Sendai virus (SeV) vector comprising a nucleic acid that is modified in the phosphoprotein (P) gene to encode a mutant P protein lacking amino acids 2-77, wherein the nucleic acid further encodes a chimeric F protein comprising a respiratory syncytial virus (RSV) F ectodomain, or an immunogenic fragment or mutant thereof, a RSV F transmembrane domain, or a functional fragment or mutant thereof, and a SeV F cytoplasmic domain, or any fragment or mutant thereof, or wherein the nucleic acid further encodes a F protein comprising a RSV F ectodomain, or an immunogenic fragment or mutant thereof, and a RSV F transmembrane domain, or a functional fragment or mutant thereof.
A method for the treatment of RSV infections or RSV infection-related diseases in a mammal the method comprising administering to said mammal a genome replication-deficient Sendai virus (SeV) vector comprising a nucleic acid that is modified in the phosphoprotein (P) gene to encode a mutant P protein lacking amino acids 2-77, wherein the nucleic acid further encodes a chimeric F protein comprising a respiratory syncytial virus (RSV) F ectodomain, or an immunogenic fragment or mutant thereof, a RSV F transmembrane domain, or a functional fragment or mutant thereof, and a SeV F cytoplasmic domain, or any fragment or mutant thereof, or wherein the nucleic acid further encodes a F protein comprising a RSV F ectodomain, or an immunogenic fragment or mutant thereof, and a RSV F transmembrane domain, or a functional fragment or mutant thereof.
Dependencies are inferred from the claim text.